A #cattle-derived #human #H5N1 isolate suppresses innate #immunity despite efficient #replication in human respiratory #organoids
Abstract
The H5N1 high pathogenicity avian influenza virus (HPAIV) of clade 2.3.4.4b, which spreads globally via wild birds, has become a major public health concern because it can infect a variety of mammals, including humans. In 2024, infection of dairy cattle with H5N1 HPAIV clade 2.3.4.4b was confirmed in the United States, and subsequent human cases were reported. Although these viruses are highly pathogenic in animal models, human infections have generally been mild, revealing a striking discrepancy. Here, we characterized the cattle-derived human H5N1 isolate A/Texas/37/2024 (TX37-H5N1) using three-dimensional human respiratory organoids derived from induced pluripotent stem (iPS) cells. Despite efficient replication, TX37-H5N1 induced minimal interferon and inflammatory cytokine responses. Bulk and single-cell RNA sequencing revealed reduced STAT1-mediated transcriptional activity in TX37-H5N1-infected organoids compared to the historic H5N1 human isolate A/Vietnam/1203/2004. These findings suggest that TX37-H5N1 fails to trigger the strong innate responses, including robust cytokine production, that are typically associated with severe H5N1 disease and are thought to contribute to cytokine storm-medicated pathogenesis. This attenuated response may help explain the discrepancy between the high pathogenicity of TX37-H5N1 in animal models and its mild clinical presentation in humans. While zoonotic influenza risk is often assessed using cell lines or animal models, our study highlights the value of using human respiratory organoids to evaluate human-specific virus-host interactions. This platform provides a complementary tool for assessing the risk of emerging avian influenza viruses.
Competing Interest Statement
The authors have declared no competing interest.
Funder Information Declared
Japan Society for the Promotion of Science, JP24K09264
Japan Agency for Medical Research and Development, JP223fa627005, JP243fa627003h0003, JP24gm1810009, JP223fa627002, JP233fa827018
Japan Agency for Medical Research and Development, JP21gm1610005, JP22gm1610010
Japan Science and Technology Agency, JPMJMS2025
Takeda Science Foundation, https://ror.org/02y123g31
Source: BioRxIV, https://www.biorxiv.org/content/10.1101/2025.11.02.684669v1
____

Comments
Post a Comment